dopamine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
dopaminergic agents dopamine derivatives used as cardiac stimulant/antihypertensives/diuretics	947	51-61-6

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: dopamine oxytyramine dopamin dophamine hydroxytyramin dopamine hydrochloride dopamine HCl

One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Molecular weight: 153.18 Formula: C8H11NO2 CLOGP: 0.17 LIPINSKI: 0 HAC: 3 HDO: 3 TPSA: 66.48 ALOGS: -1.31 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.50	g	P

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	470 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.74 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	65.90 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.87 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.42 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1974	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	159.05	103.96	53	140	101571	2256321
Cardiac arrest	122.74	103.96	29	164	14901	2342991

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug ineffective	96.83	61.35	37	147	63764	1682833
Hypotension	61.91	61.35	22	162	29632	1716965

Pharmacologic Action:

Source	Code	Description
ATC	C01CA04	CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents
CHEBI has role	CHEBI:38147	cardiotonic drug
CHEBI has role	CHEBI:35522	beta-adrenergic agonist
CHEBI has role	CHEBI:48560	dopaminergic agent
CHEBI has role	CHEBI:35524	sympathomimetic agent
FDA EPC	N0000175570	Catecholamine
FDA CS	M0003647	Catecholamines
MeSH PA	D002316	Cardiotonic Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D020011	Protective Agents
MeSH PA	D013566	Sympathomimetics

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Low cardiac output syndrome	indication	44088000
Low blood pressure	indication	45007003
Decompensated cardiac failure	indication	195111005
Sinus bradycardia	off-label use	49710005
Acute nephropathy	off-label use	58574008
Tachyarrhythmia	contraindication	6285003
Hypovolemia	contraindication	28560003
Ventricular arrhythmia	contraindication	44103008
Acidosis	contraindication	51387008
Pheochromocytoma	contraindication	302835009
Hypoxia	contraindication	389086002
Occlusive Vascular Disease	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.96	acidic
pKa2	12.98	acidic
pKa3	10.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Ki	5		WOMBAT-PK	CHEMBL
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Kd	4.19		CHEMBL
Melatonin receptor type 1A	GPCR	P48039	MTR1A_HUMAN		Ki	5.15		CHEMBL
Melatonin receptor type 1B	GPCR	P49286	MTR1B_HUMAN		Ki	5.04		CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.19		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.08		PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	AGONIST	Ki	9		WOMBAT-PK
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		IC50	8.18		WOMBAT-PK
Trace amine-associated receptor 1	GPCR	Q96RJ0	TAAR1_HUMAN		Ki	6.37		WOMBAT-PK
Dopamine beta-hydroxylase	Enzyme	P09172	DOPO_HUMAN		Km	3		WOMBAT-PK
FAD-linked sulfhydryl oxidase ALR	Enzyme	P55789	ALR_HUMAN		AC50	5.85		CHEMBL
Lysine-specific demethylase 4E	Enzyme	B2RXH2	KDM4E_HUMAN		IC50	5.52		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	AGONIST	Ki	9		WOMBAT-PK
Dopamine receptor	GPCR		DRD1_BOVIN DRD2_BOVIN		IC50	8.43		CHEMBL
Sodium-dependent dopamine transporter	Transporter		SC6A3_RAT		IC50	6.70		CHEMBL
Adenylate cyclase	Enzyme		ADCY2_RAT ADCY3_RAT ADCY4_RAT ADCY5_RAT ADCY6_RAT ADCY8_RAT D4A3N4_RAT Q8CFM9_RAT		EC50	5.46		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_BOVIN		Ki	8.15		CHEMBL
Beta-1 adrenergic receptor	GPCR		ADRB1_RAT		Ki	5		CHEMBL
D(4) dopamine receptor	GPCR		DRD4_RAT		EC50	8.62		CHEMBL
Dopamine receptor	GPCR		DRD1_RAT DRD2_RAT DRD3_RAT DRD4_RAT DRD5_RAT		IC50	5.27		CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2A_RAT ADA2B_RAT ADA2C_RAT		Ki	7.24		CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		Ki	4.85		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	8.74		CHEMBL
Beta-2 adrenergic receptor	GPCR		ADRB2_CANFA		Ki	4.30		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_RAT		Ki	6.82		CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	8.35		CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		Ki	7.96		CHEMBL
Opioid receptor	GPCR		OPRD_RAT OPRK_RAT OPRM_RAT SGMR1_RAT		IC50	5.52		CHEMBL
Adenosine A2b receptor	GPCR		AA2BR_RAT		Ki	6.01		CHEMBL
M18 aspartyl aminopeptidase	Unclassified		Q8I2J3_PLAF7		IC50	5.70		CHEMBL

External reference:

ID	Source
D004298	MESH_DESCRIPTOR_UI
4019733	VUID
N0000147825	NUI
C0013030	UMLSCUI
D00633	KEGG_DRUG
7L3E358N9L	UNII
62-31-7	SECONDARY_CAS_RN
59187003	SNOMEDCT_US
6641	MMSL
3628	RXNORM
412383006	SNOMEDCT_US
d00216	MMSL
4019733	VANDF
004721	NDDF
681	PUBCHEM_CID
CHEBI:18243	CHEBI
CHEMBL59	ChEMBL_ID
CHEMBL1557	ChEMBL_ID
DB00988	DRUGBANK_ID
2417	INN_ID
LDP	PDB_CHEM_ID
940	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9252	INJECTION	40 mg	INTRAVENOUS	ANDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9253	INJECTION	80 mg	INTRAVENOUS	ANDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9254	INJECTION	40 mg	INTRAVENOUS	ANDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9255	INJECTION	80 mg	INTRAVENOUS	ANDA	11 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1840	INJECTION	80 mg	INTRAVENOUS	EXPORT ONLY	13 sections
MYOCARD-DX	HUMAN PRESCRIPTION DRUG LABEL	2	0264-1880	INJECTION	800 mg	INTRAVENOUS	EXPORT ONLY	13 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1005	INJECTION, SOLUTION	80 mg	INTRAVENOUS	NDA	12 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1007	INJECTION, SOLUTION	160 mg	INTRAVENOUS	NDA	12 sections
Dopamine Hydrochloride and Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0338-1009	INJECTION, SOLUTION	320 mg	INTRAVENOUS	NDA	12 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-5820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7808	INJECTION, SOLUTION	0.80 mg	INTRAVENOUS	NDA	13 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7809	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
Dopamine Hydrochloride in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0409-7810	INJECTION, SOLUTION	3.20 mg	INTRAVENOUS	NDA	13 sections
DOPamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-9104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1220	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HCI	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1291	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	12 sections
DOPAMINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1316	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
DOPAMINE HCI IN 5% DEXTROSE	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1458	INJECTION, SOLUTION	1.60 mg	INTRAVENOUS	NDA	13 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-104	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Dopamine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	52584-820	INJECTION, SOLUTION, CONCENTRATE	40 mg	INTRAVENOUS	NDA	11 sections
Viatrexx-Neuro 3	HUMAN PRESCRIPTION DRUG LABEL	15	73069-373	INJECTION	201 [kp_C]	INTRAVENOUS	unapproved drug other	11 sections
Viatrexx-Neuro	HUMAN PRESCRIPTION DRUG LABEL	4	73069-375	INJECTION	201 [kp_C]	INTRAVENOUS	unapproved drug other	11 sections